Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple test predict immunotherapy outcomes for pancreatic cancer?

NCT ID NCT07271823

Knowledge-focused Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop a way to predict which patients with advanced pancreatic cancer will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 100 participants before and during treatment. By analyzing these samples, they hope to create a model that forecasts treatment response, potentially personalizing cancer care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which pancreatic cancer patients will benefit from immunotherapy, leading to more personalized and effective treatment plans.
What could go wrong
This is an early observational study, not a treatment trial. The predictive model may not be accurate enough for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Locally advanced or metastatic pancreatic ductal adenocarcinoma confirmed histologically or cytologically as unresectable

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older; 2. Histologically or cytologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma that is unresectable; 3. No prior systemic anticancer therapy; 4. At least one measurable lesion confirmed according to RECIST 1.1 criteria; 5. Receiving first-line treatment with an immunotherapy combined with chemotherapy regimen; 6. Signed informed consent. Exclusion Criteria: 1. Active malignancy other than pancreatic cancer within the past 5 years or concurrently; 2. Prior receipt of immunotherapy or anti-angiogenic therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer non-resectable are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer non-resectable

Contacts and locations

Locations

  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

    Zhejiang, Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.